Discovering new treatments, unlocking possibilities

Evommune is a clinical stage, biotechnology company dedicated to the development of transformative medicines for inflammatory diseases



By leveraging our innovative tissue-based approach, we can accelerate discovery of novel therapies and better predict clinical outcomes

Millions struggle with inflammatory conditions

That's why we're here.

Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.1

Many immunology-focused medications give patients a temporary fix to a longer-term problem, addressing symptom control rather than the root cause of disease.

Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.

Reference: 1. Pahwa R, Goyal A, Bansal P, et al. Chronic Inflammation. StatPearls Publishing. 2022. Accessed October 6, 2022. https://pubmed.ncbi.nlm.nih.gov/29630225/

Our approach

Tissue as a window to inflammation

We believe in the power of human tissue to better understand the immune system and uncover new pathways to vital medicines. By using our dynamic human tissue-based approach and platform as a window into the immune system, we can more quickly and efficiently choose the best candidates, moving the development process further, faster, and with less risk.

Improving patients’ lives beyond symptoms

We’re highly attuned to the serious comorbidities associated with systemic inflammatory diseases, because patients are at risk for more than they may realize. Our aim is to address the entire immune system—not just the presenting issue—and provide clear insights into what’s coming down the road for patients’ health to improve their quality of life, halt disease progression, and reduce mortality.

Next level partners, inside and out

We want to have the best people working on the best science, and that means being—and finding—excellent partners. We collaborate with exceptional teams to sharpen and advance the industry in order to take massive leaps forward and get better medicines to patients faster.

Our pipeline

We’re committed to evolving immunology. We believe we can more rapidly identify impactful therapies by leveraging our innovative human tissue-based approach. Our pipeline includes programs that are targeted to address highly prevalent inflammatory diseases. Our goal is to drive meaningful advances for patients with these diseases, designing all our programs to deliver best-in-class profiles.

Target Program Route Discovery Pre-IND Phase 1 Phase 2 Phase 3 Commercial Rights
IRAK4 EVO101 Topical
Atopic Dermatitis
Worldwide
MRGPRX2 EVO756 Oral
Urticaria
Interstitial Cystitis
Worldwide
RORyt EVO390 Topical
Psoriasis
Worldwide
PKCϴ Discovery Oral
Autoimmune Diseases
Worldwide
Target IRAK4
Program EVO101
Route Oral
Phase Phase 2
Commercial Rights Worldwide
Target MRGPRX2
Program EVO756
Route Oral
Phase Discovery
Commercial Rights Worldwide
Target RORγt
Program EVO390
Route Topical
Phase Pre-IND
Commercial Rights Worldwide
Target PKCϴ
Program Discovery
Route Oral
Phase Discovery
Commercial Rights Worldwide

IRAK4 (EVO101)

MRGPRX2 (EVO756)

RORγt (EVO390)

Protein Kinase C Theta (PKCϴ)

Reference: 2. Kuhn, H., et al., Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. J Allergy Clin Immunol, 2021;147(2):456-469. 3. Corbière A, Loste A, Gaudenzio N. MRGPRX2 sensing of cationic compounds-A bridge between nociception and skin diseases? Exp Dermatol. 2021;30(2):193-200. 4. Ferrer M, Nuñez-Córdoba JM, Luquin E. Serum total tryptase levels are increased in patients with active chronic urticaria. Clin Exp Allergy. 2010; 40(12):1760-1766.

End-to-end experts in drug discovery and development

We’ve done this before, and we’ll do it again, building off our extensive R&D experience in immunology and connecting diverse disciplines to discover and develop effective therapies that address inflammatory diseases. Our team has decades of combined expertise across all stages of discovery and development — we’ve built great companies and developed therapies that have helped tens of millions of patients worldwide.

“Available medicines have made progress treating inflammation, but we know there’s a need for safer, more effective therapies. That’s where Evommune will make a difference—we are committed to science and innovation to improve patients' lives.”

Luis Peña

President & CEO, Evommune

Our leadership

Luis Peña

President and Chief Executive Officer

Eugene A. Bauer, MD

Chief Medical Officer

Kyle Carver, MBA, CPA

Chief Financial Officer

Gregory S. Moss, Esq.

Chief Corporate Strategy and Legal Officer

Jeegar Patel, PhD

Chief Scientific Officer

Janice Drew, MPH

Executive Vice President, Operations

Hans Hofland, PhD

Senior Vice President, Research

Lou Sehl, PhD

Senior Vice President, Technical Operations

Board of Directors

Luis Peña

President and Chief Executive Officer

Eugene A. Bauer, MD

Chief Medical Officer

David E. Cohen, MD, MPH

Professor of Dermatology, Vice Chairman of Clinical Affairs, Chief of Allergy and Contact Dermatitis, Director of Occupational and Environmental Dermatology

Rob Hopfner, RPh, PhD, MBA

Managing Partner at Pivotal bioVenture Partners

Benjamin F. McGraw, III, PharmD

Chairman and Chief Executive Officer at TheraVida

Gilles Nobécourt

Partner at Andera Partners

Felice Verduyn-van Weegen

Partner at EQT

Scientific Advisors

Russ B. Altman, MD, PhD

Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and, by courtesy, Computer Science, Stanford University

Brian Berman, MD, PhD

Professor Emeritus, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine

James Q. Del Rosso, DO, FAOCD, FAAD

Adjunct Clinical Professor (Dermatology), Touro University Nevada

Emma Guttman-Yassky, MD, PhD

Sol and Clara Kest Professor of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai

James G. Krueger, MD, PhD

Professor, Laboratory Head, The Rockefeller University

Mark G. Lebwohl, MD

Waldman Professor and Chairman, Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai

Dan R. Littman, MD, PhD

Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine and Investigator of the Howard Hughes Medical Institute

Georg Stingl, MD

Professor Emeritus, Department of Dermatology, Medical University of Vienna

Join us

We’re a lively, engaging, deeply passionate team dedicated to our mission to help people with inflammatory diseases. We care about creating a welcoming environment where the industry’s greatest talent comes to stay and do the best work of their careers.

We value individuals who are talented at what they do and disciplined and agile in how they do it. Do you have deep knowledge of your domain and have high emotional intelligence? Are you ready to share your expertise and bring passion to your work? Do you thrive as part of a dynamic, fun team and care about your colleagues’ success?

If so, reach out, and let’s discuss our open positions: careers@evommune.com.

Evommune is an equal opportunity employer and does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, nondisqualifying physical or mental disability, national origin, veteran status, or any other characteristic protected by applicable law.

We’re a lively, engaging, deeply passionate team dedicated to our mission to help people with inflammatory diseases. We care about creating a welcoming environment where the industry’s greatest talent comes to stay and do the best work of their careers.

We value individuals who are talented at what they do and disciplined and agile in how they do it. Do you have deep knowledge of your domain and have high emotional intelligence? Are you ready to share your expertise and bring passion to your work? Do you thrive as part of a dynamic, fun team and care about your colleagues’ success?

If so, reach out, and let’s discuss our open positions: careers@evommune.com.

Evommune is an equal opportunity employer and does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, nondisqualifying physical or mental disability, national origin, veteran status, or any other characteristic protected by applicable law.

Connect

For questions and media or partnership inquiries, please complete the form below. For partnership inquiries, please email business.inquiry@evommune.com.